消退素D1在骨缺损修复领域中的研究进展

doi:10.13701/j.cnki.kqyxyj.2026.08.001

摘要/Abstract

摘要： 由创伤、感染或先天因素导致的骨缺损是临床治疗的难点,其修复过程涉及复杂的炎症与再生调控。特异性促消退介质(specialized proresolving mediators, SPMs)是一类内源性脂类介质,能够主动促进炎症消退和组织修复。消退素D1(resolvin D1,RvD1)作为来源于Omega-3多不饱和脂肪酸的SPM,在调控炎症反应、促进组织修复方面显示出重要作用。本文围绕RvD1的生物学特性、作用机制、在口腔颌面部骨缺损修复中的应用及其前景与挑战进行综述,以期为骨修复治疗策略的优化提供新思路。

关键词: 消退素D1, 骨再生, 骨缺损, 骨组织修复

Abstract: Bone defects resulting from trauma, infection, or congenital factors present significant challenges in clinical treatment, as their repair involves complex inflammatory and regenerative regulation. Specialized proresolving mediators (SPMs) are a class of endogenous lipid mediators that actively promote inflammation resolution and tissue repair. Resolvin D1 (RvD1), an SPM derived from omega-3 polyunsaturated fatty acids, plays a crucial role in regulating inflammatory responses and promoting tissue regeneration. This review focuses on the biological characteristics and mechanisms of RvD1, its application in the repair of oral and maxillofacial bone defects, and its prospects and challenges, aiming to provide new insights for optimizing bone repair therapeutic strategies.

Key words: resolvin D1, bone regeneration, bone defect, bone tissue repair

令狐昌凤, 唐正龙. 消退素D1在骨缺损修复领域中的研究进展[J]. 口腔医学研究, 2026, 42(8): 639-643.

LINGHU Changfeng, TANG Zhenglong. Research Progress on Resolvin D1 in Field of Bone Defect Repair[J]. Journal of Oral Science Research, 2026, 42(8): 639-643.

参考文献

[1] Zhao D, Saiding Q, Li Y, et al. Bone organoids: Recent advances and future challenges [J]. Adv Healthc Mater, 2024, 13(5): 2302088.
[2] Jin Y, Huang Y, Wang J, et al. From injury to integrity: tissue engineering solutions in combined bone repair and regeneration and muscle repair [J]. Burns Trauma, 2025, 13: tkaf052.
[3] Liu W, Zhao H, Zhang C, et al. In situ activation of flexible magnetoelectric membrane enhances bone defect repair [J]. Nat Commun, 2023, 14: 4091.
[4] Wang W, Zeng W, Tu Q, et al. Advances in tissue engineering for the repair of growth plate injuries [J]. Front Bioeng Biotechno, 2025, 13: 1608923.
[5] Jakiewicz Ł, Romaszko-Wojtowicz A, Chmielewski G, et al. Effect of myokines on bone tissue metabolism: a systematic review [J]. Bone, 2025, 201: 117654.
[6] Sousa LG, Correia-da-Silva G, Teixeira N, et al. Specialized pro-resolving mediators: key regulators in placental function and pregnancy complications [J]. J Mol Med (Berl), 2025, 103(8): 885-897.
[7] Nshimiyimana R, Simard M, Teder T, et al. Biosynthesis of resolvin D1, resolvin D2, and RCTR1 from 7,8(S,S)-epoxytetraene in human neutrophils and macrophages [J]. Proc Natl Acad Sci U S A, 2024, 121(37): e2405821121.
[8] Huang L, Wu J, Cao J, et al. Resolvin D1 inhibits T follicular helper cell expansion in systemic lupus erythematosus [J]. Scand J Rheumatol, 2024, 53(4): 276-283.
[9] Rovai EDS, Polassi M, Silveira MID, et al. Impact of specialized pro-resolving lipid mediators on craniofacial and alveolar bone regeneration: scoping review [J]. Braz Dent J, 2024, 35: e24-6133.
[10] Flippen A, Khasabova IA, Simone DA, et al. Systemic administration of resolvin D1 reduces cancer-induced bone pain in mice: lack of sex dependency in pain development and analgesia [J]. Cancer Med, 2024, 13(15): e70077.
[11] Yang M, Song XQ, Han M, et al. The role of resolvin D1 in liver diseases [J]. Prostaglandins Other Lipid Mediat, 2022, 160: 106634.
[12] Amin Mohedin J, Rezaiemanesh A, Asadi S, et al. Resolvin D1 (Rvd1) attenuates in vitro LPS-stimulated inflammation through downregulation of miR-155, miR-146, miR-148 and krupple like factor 5 [J]. Rep Biochem Mol Biol, 2024, 12(4): 566-574.
[13] Gao J, Su Y, Wang Z. Lung inflammation resolution by RvD1 and RvD2 in a receptor-dependent manner [J]. Pharmaceutics, 2023, 15(5): 1527.
[14] Li L, Liao J, Zhang Y, et al. Single cell and spatial transcriptomics define a proinflammatory and profibrotic niche after kidney injury [J]. Adv Sci (Weinh), 2026, 13(2): e03691.
[15] Martinez-Campanario M, Cortés M, Han L, et al. Lipid-laden macrophages in atherosclerosis and cancer [J]. Semin Cancer Biol, 2025, 117:38-56.
[16] Wu J, Gao J, Yi L, et al. Protective effects of resolvin D1 in pseudomonas aeruginosa keratitis [J]. Mol Immunol, 2023, 158: 35-42.
[17] Shan K, Feng N, Cui J, et al. Resolvin D1 and D2 inhibit tumour growth and inflammation via modulating macrophage polarization [J]. J Cell Mol Med, 2020, 24(14): 8045-8056.
[18] Groenen AG, Lipscomb M, Bossardi Ramos R, et al. Resolvin D1 suppresses macrophage senescence and splenic fibrosis in aged mice [J]. Prostaglandins Leukot Essent Fatty Acids, 2024, 202: 102634.
[19] Xiang SY, Ye Y, Yang Q, et al. RvD1 accelerates the resolution of inflammation by promoting apoptosis of the recruited macrophages via the ALX/FasL-FasR/caspase-3 signaling pathway [J]. Cell Death Discov, 2021, 7(1): 339.
[20] Jiang X, Liu J, Li S, et al. The effect of resolvin D1 on bone regeneration in a rat calvarial defect model [J]. J Tissue Eng Regen Med, 2022, 16(11): 987-997.
[21] de Almeida JM, Turini HD, Matheus HR, et al. Omega-3 attenuates the severity of medication-related osteonecrosis of the jaws in rats treated with zoledronate [J]. PLoS One, 2025, 20(3): e0320413.
[22] Xing Z, Liu J, Cai J, et al. The application of resolvin D1-loaded gelatin methacrylate in a rat periodontitis model [J]. Pharmaceutics, 2024, 17(1): 16.
[23] Zarrough AE, Hasturk H, Stephens DN, et al. Resolvin D1 modulates periodontal ligament fibroblast function [J].J Periodontol, 2023, 94(5): 683-693.
[24] Cai J, Liu J, Yan J, et al. Impact of resolvin D1 on the inflammatory phenotype of periodontal ligament cell response to hypoxia [J]. J Periodontal Res, 2022, 57(5): 1034-1042.
[25] 邱莞迪,崔彩云,李言君.消退素在牙髓、根尖周及牙周组织炎症环境中的活髓保存及再生作用[J].中国组织工程研究, 2021, 25(32): 5191-5196.
[26] Pinto N, Klein Y, David E, et al. Resolvin D1 improves allograft osteointegration and directly enhances osteoblasts differentiation [J]. Front Immunol, 2023, 14: 1086930.
[27] Klein Y, Levin-Talmor O, Berkstein JG, et al. Resolvin D1 shows osseous-protection via RANK reduction on monocytes during orthodontic tooth movement [J]. Front Immunol, 2022, 13: 928132.
[28] Schulze F, Lang A, Schoon J, et al. Scaffold guided bone regeneration for the treatment of large segmental defects in long bones [J]. Biomedicines, 2023, 11(2): 325.
[29] Wang Z, Zhu J, Mi B, et al. Photocatalytic CO-releasing spray hydrogel for in situ postoperative cancer treatment [J]. Bioact Mater, 2025, 53: 893-907.
[30] Chen L, Chen G, Hu K, et al. Combined photothermal and photodynamic therapy enhances ferroptosis to prevent cancer recurrence after surgery using nanoparticle-hydrogel composite [J]. Chem Engineer J, 2023, 468: 143685.
[31] Tang X, Ren J, Wei X, et al. Exploiting synergistic effect of CO/NO gases for soft tissue transplantation using a hydrogel patch [J]. Nat Commun, 2023, 14(1): 2417.
[32] Liu Z, Wu J, Luo Z, et al. 3D biofabrication of microporous hydrogels for tissue engineering [J]. Adv Healthc Mater, 2025, 14(3): e2403583.
[33] Le G, Li J, Li H, et al. Rationalizing hydrogel-integrated peroxidase-mimicking nanozymes for combating drug-resistant bacteria and colorimetric sensing [J]. Int J Biol Macromol, 2025, 291: 138576.
[34] Ji H, Zhang H, Wang Y, et al. Feasibility of caffeic acid as a crosslinking agent in modifying acellular extracellular matrices [J]. Biochem Biophys Res Commun, 2023, 677: 182-189.
[35] Xing Z, Liang J, Sun Y, et al. Novel resolvin D1-loaded biologics as an advanced approach for inflammation control and tissue regeneration: preparation and characterization [J]. Pharmaceutics, 2025, 17(5): 643.
[36] Zhu M, Li X, Xiao L, et al. 3D-printed microfibers encapsulating stem cells in scaffold with tri-culture and two-stage metformin release for bone/vasculature/nerve regeneration in rats [J]. Bioact Mater, 2025, 51: 399-413.
[37] Bozkurt SB, Hakki SS, Kantarci A. Differential effects of resolvin D1 and resolvin E1 on cementoblast function [J]. J Periodontol, 2023, 94(11): 1351-1362.
[38] Park K, Otte A, Sharifi F, et al. Potential roles of the glass transition temperature of PLGA microparticles in drug release kinetics [J]. Mol Pharm, 2021, 18(1): 18-32.
[39] Aguilar-Rabiela AE, Homaeigohar S, González-Castillo EI, et al. Comparison between the astaxanthin release profile of mesoporous bioactive glass nanoparticles (MBGNs) and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV)/MBGN composite microspheres [J]. Polymers (Basel), 2023, 15(11): 2432.